Sepracor, GSK eszopiclone deal

SEPR granted GlaxoSmithKline (LSE:GSK; GSK) exclusive rights to market eszopiclone to treat insomnia outside of North America and Japan. In July, SEPR submitted an MAA to EMEA for the non-benzodiazepi...